Committees

Summary of Recommendations from the 105th meeting of the Medicines Assessment Advisory Committee held in Wellington on Tuesday 27 June 2017 at 9:30 am

5.	Applications for consent to distribute a new medicine under section 20 of the Medicines Act 1981 (referred by the Minister of Health under section 22(2))
5.1	Azmasol HFA (salbutamol sulfate) aerosol inhaler, 100 mcg metered dose (TT50-9392) Beximco Pharmaceuticals New Zealand Limited The application was withdrawn by the applicant company, prior to the meeting, on 19 June 2017.
5.2	Diclofenac Mylan (sodium diclofenac) 20 mg and 50 mg enteric coated tablets (TT50-9469, a) Mylan New Zealand Limited The application was withdrawn by the applicant company, prior to the meeting, on 25 May 2017.
7	General business
7.1	Observers That the Medsafe consultation regarding Observers at Ministerial Advisory Committees should proceed following consideration by the Medicines Adverse Reactions Committee.